Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34560256)

  • 1. Optimization strategies for expression of a novel bifunctional anti-PD-L1/TGFBR2-ECD fusion protein.
    Gao ZZ; Li C; Chen G; Yuan JJ; Zhou YQ; Jiao JY; Nie L; Qi J; Yang Y; Chen SQ; Wang HB
    Protein Expr Purif; 2022 Jan; 189():105973. PubMed ID: 34560256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy.
    Wu ZH; Li N; Gao ZZ; Chen G; Nie L; Zhou YQ; Jiang MZ; Chen Y; Chen J; Mei XF; Hu F; Wang HB
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
    Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
    Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
    De Luca R; Neri D
    Cancer Immunol Immunother; 2018 Sep; 67(9):1381-1391. PubMed ID: 29971465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
    Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
    J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
    Chang HW; Frey G; Liu H; Xing C; Steinman L; Boyle WJ; Short JM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
    Gong B; Kiyotani K; Sakata S; Nagano S; Kumehara S; Baba S; Besse B; Yanagitani N; Friboulet L; Nishio M; Takeuchi K; Kawamoto H; Fujita N; Katayama R
    J Exp Med; 2019 Apr; 216(4):982-1000. PubMed ID: 30872362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
    Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
    Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.
    Cui X; Jia H; Xin H; Zhang L; Chen S; Xia S; Li X; Xu W; Chen X; Feng Y; Wei X; Yu H; Wang Y; Zhan Y; Zhu X; Zhang X
    Front Immunol; 2021; 12():778978. PubMed ID: 34925354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
    Hira-Miyazawa M; Nakamura H; Hirai M; Kobayashi Y; Kitahara H; Bou-Gharios G; Kawashiri S
    Int J Oncol; 2018 Feb; 52(2):379-388. PubMed ID: 29345283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
    Liu H; Shen J; Lu K
    Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design.
    Zou S; Liu J; Sun Z; Feng X; Wang Z; Jin Y; Yang Z
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):185-193. PubMed ID: 31745591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
    Tanoue K; Rosewell Shaw A; Watanabe N; Porter C; Rana B; Gottschalk S; Brenner M; Suzuki M
    Cancer Res; 2017 Apr; 77(8):2040-2051. PubMed ID: 28235763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.